Propranolol as a potentially novel treatment of arteriovenous malformations: from bench to bedside

  • Background: Propranolol is a non-selective blocker of the β-adrenergic receptor and has been used for treatment of proliferative infantile hemangiomas. The vasoconstrictive and antiangiogenic effects of propranolol led us to explore its potential application for the treatment of AVMs. Methods: AVM tissue was cultured after surgical resection in the presence of 100μM propranolol or solvent DMSO. After incubation for 72 hours, tissue was harvested for testing. The expression levels of SDF1α, CXCR4, VEGF and HIF-1 was measured by rt-PCR. Furthermore, data of patients in 2 vascular centres harboring AVM was retrospectively interrogated for a time period of 20 years. The database included information about hemorrhage, AVM size and antihypertensive medication. Descriptive analyses were performed, focusing on the risk of hemorrhage, size of the lesion at presentation and clinical follow-up in patients on β-blocker medication versus those who were not. Results: Among 483 patients, 73 (15%) were under β-blocker-treatment. 48% AVMs presented with hemorrhage at diagnosis. Patients under β-blocker-treatment had a lower risk of hemorrhage at the time of diagnosis in a univariate analysis (p<0,0001;OR13). Patients under β-blocker-treatment showed a significant higher chance for a lower Spetzler-Martin-grade ≤III (p<0,0001;OR6,5) and a lower risk for the presence of an associated aneurysm (p<0,0001;OR3,6). Multivariate analysis including Spetzler-Martin-Grading, young age ≤50, presence of associated aneurysm and β-blocker-treatment showed reduced risk for hemorrhage under β-blocker-treatment (p<0,01,OR0,2). The expression of CXCR4 was suppressed by propranolol most likely through the HIF-1-pathways. The gene-expression of vasculogenesis factors was decreased in with propranolol incubated AVMs. Conclusion: β-Blocker medication seems to be associated with a decreased risk of AVM-related hemorrhage and AVM-size at presentation or during follow-up. Propranolol inhibits SDF1α-induced vasculogenesis by suppressing the expression of CXCR4 most likely through the HIF-1-pathways. Therefore, SDF1α/CXCR4 axis plays an important role in the vasculogenesis and migration of inflammatory cells in AVM lesions.

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Author:Sepide KashefiolaslORCiDGND, Matthias LeisegangORCiDGND, Rajan Patel, Peter KanORCiD, Christian FörchORCiDGND, Richard Klaus Frieder Du Mesnil de RochemontGND, Volker SeifertORCiD, Ralf BrandesORCiDGND, Vincent Matthias PrinzGND, Jürgen KonczallaORCiDGND, Jan-Karl BurkhardtORCiD, Marcus Alexander CzabankaORCiDGND
URN:urn:nbn:de:hebis:30:3-782907
DOI:https://doi.org/10.1016/j.bas.2022.101207
ISSN:2772-5294
Parent Title (English):Brain and Spine
Publisher:Elsevier
Place of publication:Amsterdam
Document Type:Conference Proceeding
Language:English
Date of Publication (online):2022/10/17
Date of first Publication:2022/10/17
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Contributing Corporation:European Congress of Neurosurgery (2022 : Belgrad)
Release Date:2023/10/28
Volume:2
Issue:Supplement 2, 101207
Article Number:101207
Page Number:1
HeBIS-PPN:513387080
Institutes:Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - CC BY-NC-ND - Namensnennung - Nicht kommerziell - Keine Bearbeitungen 4.0 International